- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03659435
Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)
September 18, 2019 updated by: SocraTec R&D GmbH
Open, Randomized, 2-period, 2-sequence, Cross-over Relative Bioavailability Study to Investigate the Pharmacokinetics and to Assess the Bioequivalence of a Rivastigmine Test Patch Formulation 9.5 mg/24 h (Twice Weekly Patch) Compared to the Reference Exelon® 9.5 mg/24 h (Once Daily Patch) Applied for 11 Days
The present clinical trial will be conducted in order to compare the bioavailability of rivastigmine and to assess bioequivalence at steady-state of the Test product RID-TDS 9.5 mg/24 h (Luye Pharma AG, Germany) and the marketed Reference product Exelon® 9.5 mg/24 h transdermales Pflaster (Novartis Pharma GmbH, Germany) after multiple patch application.
Each of both treatments will last for 11 days with a washout period of 14 days between the treatments.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
58
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Thüringen
-
Erfurt, Thüringen, Germany, 99084
- SocraTec R&D GmbH, Clinical Pharmacology Unit
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 53 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- sex: male
- age: 18-55 years, inclusive
- body-mass index2 (BMI): ≥18.5 kg/m² and ≤ 30.0 kg/m²
- good state of health as determined by no clinically significant diseases captured in the medical history or evidence of clinically significant findings on physical examination (including vital sign) and/or ECG, as determined by the investigator
- non-smoker or ex-smoker for at least 1 month
- written informed consent, after having been informed about benefits and potential risks of the clinical trial, as well as details of the insurance taken out to cover the subjects participating in the clinical trial
Exclusion Criteria:
- existing cardiac and/or haematological diseases or pathological findings, which might interfere with the safety or tolerability of the active ingredient (especially sick sinus syndrome or conduction defects such as sino-atrial block, atrio-ventricular block)
- existing hepatic and/or renal diseases or pathological findings, which might interfere with the safety or tolerability, and/or pharmacokinetics of the active ingredient (especially predisposition to urinary obstruction and seizures)
- existing gastrointestinal diseases or pathological findings, which might interfere with the safety, tolerability, absorption and/or pharmacokinetics of the active ingredient (especially active gastric or duodenal ulcers or predisposition to these conditions)
- history of relevant CNS and/or psychiatric disorders and/or currently treated CNS and/or psychiatric disorders
- Subjects with chronic obstructive or other pulmonary diseases or bronchial asthma
- known allergic reactions to the active ingredients used or to constituents of the pharmaceutical preparations or previous history of application site reactions suggestive of allergic contact dermatitis with rivastigmine patch
- subjects with severe allergies or multiple drug allergies unless it is judged as not relevant for the clinical trial by the investigator
- systolic blood pressure < 90 or >139 mmHg
- diastolic blood pressure < 60 or >89 mmHg
- heart rate < 50 bpm or > 90 bpm
- body weight below 50 kg
- QTc interval > 450 ms
- laboratory values out of normal range unless the deviation from normal is judged as not relevant for the clinical trial by the investigator
- ASAT > 20% ULN, ALAT > 10% ULN, bilirubin > 20% ULN (except in case of existing Morbus Gilbert-Meulengracht deduced from anamnesis/medical history) and creatinine > 0.1 mg/dL ULN (limit of > 0.1 mg/dL correspondents to of > 9 μmol/l ULN).
- positive anti-HIV-test (if positive to be verified by western blot), HBs-AG-test or anti-HCV-test
- Presence or history of acute or chronic diseases especially of the skin, which could affect dermal absorption or metabolism, which may interfere with the bioavailability and /or the pharmacokinetics of the IMP based on assessment of the investigator
- Skin abnormality (e.g. tattoo or scar) at the application site
- acute or chronic diseases which may interfere with the pharmacokinetics of the IMP
- history of or current drug or alcohol dependence
- positive alcohol or drug test at screening examination
- regular intake of alcoholic food or beverages of ≥ 40 g pure ethanol per day
- subjects who are on a diet which could affect the pharmacokinetics of the active ingredient
- regular intake of caffeine containing food or beverages of ≥ 500 mg caffeine per day
- blood donation or other blood loss of more than 400 ml within the last 2 months prior to individual enrolment of the subject
- administration of any investigational medicinal product during the last 2 months prior to individual enrolment of the subject
- regular treatment with any systemically available medication
- subjects practising top-performance sports (more than 4 x 2 h per week)
- subjects suspected or known not to follow instructions
- subjects who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to during their participation in the clinical trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RID-TDS 9.5 mg/24 h
3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
|
3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
|
Active Comparator: Exelon® 9.5 mg/24 h
11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
|
11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC96-264
Time Frame: from 96 to 264 hours after the first patch application
|
partial area under the plasma concentration vs. time profile for the time interval 96-264 hours
|
from 96 to 264 hours after the first patch application
|
Cmax,96-264
Time Frame: from 96 to 264 hours after the first patch application
|
maximum concentration in plasma during the nominal time interval 96-264 hours
|
from 96 to 264 hours after the first patch application
|
Cmin,96-264
Time Frame: from 96 to 264 hours after the first patch application
|
absolute minimum concentration within the nominal time interval 96-264 hours
|
from 96 to 264 hours after the first patch application
|
Patch adhesion properties
Time Frame: at 96, 168 and 264 hours after the first Test patch application
|
lower one-sided 90% confidence limit for the mean of Test
|
at 96, 168 and 264 hours after the first Test patch application
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Skin irritation
Time Frame: from first patch removal until last patch removal (approx. 9 to 13 days)
|
frequency of scores for quantification of skin irritation per treatment and time point
|
from first patch removal until last patch removal (approx. 9 to 13 days)
|
Adverse events
Time Frame: approximately 7 to 12 weeks, through study completion in case of follow-up
|
descriptive evaluation of frequency and intensity, relationship to the IMP, action taken, outcome, seriousness, period and treatment
|
approximately 7 to 12 weeks, through study completion in case of follow-up
|
inhibition of plasma butyrylcholinesterase (BuChE)
Time Frame: from first patch application until 24 hours after the last patch removal
|
% inhibition of BuChE activity in plasma in comparison to baseline
|
from first patch application until 24 hours after the last patch removal
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 22, 2018
Primary Completion (Actual)
November 28, 2018
Study Completion (Actual)
November 28, 2018
Study Registration Dates
First Submitted
August 28, 2018
First Submitted That Met QC Criteria
September 5, 2018
First Posted (Actual)
September 6, 2018
Study Record Updates
Last Update Posted (Actual)
September 19, 2019
Last Update Submitted That Met QC Criteria
September 18, 2019
Last Verified
September 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1352riv18ct
- 2018-001570-18 (EudraCT Number)
- C_30410_P1_05 (Other Identifier: Luye Pharma AG / Luye Supply AG)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bioequivalence
-
Pharmtechnology LLCRecruitingBioequivalenceRussian Federation
-
Emzor Pharmaceutical Industries LimitedNot yet recruiting
-
Pharmtechnology LLCClinPharmInvest, LLCNot yet recruitingBioequivalenceRussian Federation
-
Indiana UniversityFood and Drug Administration (FDA)Completed
-
AstraZenecaCompletedBioequivalenceUnited States
-
Future University in EgyptCompleted
-
Cross Research S.A.Zambon SpACompleted
-
Laboratorios Andromaco S.A.Completed
-
Emzor Pharmaceutical Industries LimitedUnknown
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
Clinical Trials on RID-TDS 9.5 mg/24 h
-
Luye Pharma Group Ltd.SocraTec R&D GmbH; SocraMetrics GmbHCompleted
-
SocraTec R&D GmbHCompleted
-
NovartisCompleted
-
SocraTec R&D GmbHSocraMetrics GmbHCompleted
-
UCB Biopharma SRLTerminatedRestless Legs SyndromeUnited States
-
Regeneron PharmaceuticalsSyneos HealthWithdrawnAnemia | Chronic Kidney DiseaseUnited States
-
Montefiore Medical CenterNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Idiopathic ArthritisUnited States
-
M.D. Anderson Cancer CenterNot yet recruitingNon-small Cell Lung CancerUnited States
-
Yonsei UniversityNot yet recruitingNSCLCKorea, Republic of
-
GlaxoSmithKlineCompletedPostoperative Nausea and Vomiting | Nausea and Vomiting, PostoperativeSpain, United States, Philippines, Belgium, Hong Kong, Canada, Germany, Czech Republic, Thailand, Pakistan, Russian Federation